

Role of heme oxygenase-1 in the pathogenesis and tumorigenicity of Kaposi's sarcoma-associated herpesvirus

Supplementary Material




Figure S1: Targeting CD147 by RNAi reduces HO-1 expression in KSHV-infected HUVEC. HUVEC were transfected with negative control siRNA (n-siRNA) or *CD147*-siRNA for 48 h, then infected by purified KSHV (MOI ~ 10) for additional 48 h. Protein expression was measured by immunoblots.




Figure S2: Measurement of HO activity in TIVE-LTC cell extracts. TIVE-LTC were incubated with vehicle or indicated concentrations of SnPP for 24 h. HO activity in TIVE-LTC cell extracts was determined by spectrophotometric measurement of bilirubin production as described in the Methods. Error bars represent the S.E.M. for 3 independent experiments. * = $p < 0.05$; ** = $p < 0.01$.




Figure S3: Targeting HO-1 by RNAi induces TIVE-LTC cell death. (A) TIVE-LTC and parental TIVE cells were transfected with negative control siRNA (n-siRNA) or *HO-1*-siRNA for 48 h, then cell viability was measured by Annexin V-PI staining and flow cytometry analysis. (B) Protein expression was measured by immunoblots. Error bars represent the S.E.M. for 3 independent experiments. ** = $p < 0.01$.




Figure S4: SnPP treatment increases the expression of DNA damage and necrosis markers within TIVE-LTC. TIVE-LTC were incubated with vehicle or 50 μ M of SnPP for 24 h, then protein expression was measured by immunofluorescence and representative images were shown.




Figure S5: Targeting CD147 by RNAi reduces HO-1 expression in LANA-transfected HUVEC. HUVEC were transfected with negative control siRNA (n-siRNA) or *CD147*-siRNA for 48 h, then transfected with LANA construct (pCLANA) for additional 48 h. Protein expression was measured by immunoblots.

Supplemental Table 1. Primer sequences for qRT-PCR in this study.

Gene	Sequences (5' → 3')
<i>HO-1</i>	<i>sense</i> TTTGAGGAGTTGCAGGAGC
	<i>antisense</i> AGGACCCATCGGAGAAGC
<i>VEGFR1</i>	<i>sense</i> GACTAGATAGCGTCACCAG
	<i>antisense</i> AATACTCCGTAAGACCACA
<i>VEGFR2</i>	<i>sense</i> AAAGGGTGGAGGTGACTG
	<i>antisense</i> GACATAAATGACCGAGGC
<i>β-actin</i>	<i>sense</i> GGAAATCGTGCGTGACATT
	<i>antisense</i> GACTCGTCATACTCCTGCTTG